- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04142021
Safety and Feasibility Evaluation of Planning and Execution of Surgical Revascularization Solely Based on Coronary CTA and FFRCT in Patients With Complex Coronary Artery Disease (FASTTRACK CABG)
A Multicenter, Pilot Study to Evaluate Safety and Feasibility Evaluation of Planning and Execution of Surgical Revascularization Solely Based on Coronary CTA and FFRCT in Patients With Complex Coronary Artery Disease (FASTTRACK CABG)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Hideyuki Kawashima, MD
- Phone Number: +353870696945
- Email: h.kawashima429@gmail.com
Study Locations
-
-
-
Brussels, Belgium
- Recruiting
- University Hospital of Brussels
-
Contact:
- Mark La Meir, MD, PhD
-
Contact:
- Johan de Mey, MD, PhD
-
-
-
-
-
Jena, Germany
- Recruiting
- University Hospital of Jena
-
Contact:
- Torsten Doenst, MD, PhD
-
Contact:
- Ulf Teichgräber, MD
-
-
-
-
-
Milan, Italy
- Recruiting
- Centro Cardiologico Monzino
-
Contact:
- Giulio Pompilio, MD, PhD
-
Contact:
- Daniele Andreini, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients referred to CABG treatment (as assessed by 'conventional heart team') having at the time of the conventional heart team evaluation at least 1 de novo stenotic lesion (with a visually assessed DS with ≥ 50%) in all 3 major epicardial territories [left anterior descending (LAD) and/or side branch, left circumflex artery (LCX) and/or side branch, right coronary artery (RCA) and/or side branch] supplying viable myocardium with or without left main involvement
- Patients with hypoplastic RCA with absence of descending posterior and presence of a lesion in the LAD and LCX territories may be included in the trial as a 3VD equivalent. Ostial LAD plus ostial LCX may be included in the trial as a left main equivalent
- Distal vessel size should be at least 1.5 mm in diameter as visually assessed in the diagnostic angiogram (as requested by the surgeons)
- Patients with silent ischemia, chronic coronary syndrome or stabilized acute coronary syndrome with normalized (stable or decreasing) cardiac biomarker values. For patients showing elevated troponin (cTn) (e.g. non-ST elevation myocardial infarction [NSTEMI] patients) at baseline (within 24h pre-CABG) an additional blood sample must be collected prior to CABG to confirm that: a) hs-cTn or troponin I or T levels are stable, i.e. the value should be within 20% range of the value found in the first sample at baseline, or have dropped 25; b) creatine kinase-muscle/brain (CK-MB) and creatine kinase (CK) levels are within normal range. If hs-cTn or troponin I or T levels are stable or have dropped, or the CK-MB and CK levels are within normal ranges and the ECG is normal, patients may be included in the study
- All anatomical SYNTAX Scores are eligible
- Patients are amenable to coronary CTA (e.g. no claustrophobia, high heart rate not amenable to beta-blockers, poor renal function, etc., up to the discretion of the investigator)
- Patients have been informed of the nature of the study and agree to its provisions and have provided written informed consent as approved by the Ethical Committee of the respective clinical site
- Patients agree to 1-month follow-up visit including coronary CTA
Exclusion Criteria:
- Under the age of 18 years
- Unable to give informed consent
- Known pregnancy at the time of enrollment; female of childbearing potential, i.e. who are not surgically sterile or post-menopausal (defined as no menses for 2 years without an alternative cause); female who is breastfeeding at time of enrollment
- Prior PCI or CABG; history of coronary stent implantation
- Evidence of evolving or ongoing ST-elevation MI (STEMI) on ECG and/or elevated cardiac biomarkers (according to local standard hospital practice) have not returned within normal limits at the time of enrollment (non-STEMI)
- Known renal insufficiency (e.g. serum creatinine >2.5mg/dL, or creatinine clearance ≤30 mL/min), or need for dialysis, or acute kidney failure (as per physician judgment)
- Concomitant cardiac valve disease requiring surgical therapy (repair or replacement) and/or aneurysmectomy
- Single or two-vessel disease (at time of the conventional heart team consensus)
- Non-graftable distal bed in >1 vessel as assessed by the surgeon based on ICA
- Persistent atrial fibrillation or significant arrhythmias
- Known allergy to iodinated contrast
- A body mass index (BMI) of 35 or greater
- Currently participating in another clinical trial not yet at its primary endpoint
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
patients with 3-vessel disease with or without left main
Patients with 3-vessel disease with or without left main involvement referred to CABG treatment based on coronary angiography.
|
Surgery planning done based solely on coronary computed tomography angiography.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Feasibility expressed in percentage of CABG planning and execution solely based on coronary CTA in 114 candidates for CABG (i.e. the 'CTA heart team' and the operator being blind for the ICA). [percentage/rate].
Time Frame: 2 weeks after enrollment
|
2 weeks after enrollment
|
Safety: The rate of graft stenosis [≥ 50% diameter stenosis (DS) - 99% DS] or occlusion (100% DS) either at the ostium, in the shaft or at the level of the sequential anastomosis or at the distal anastomosis of each individual graft based on coronary CTA
Time Frame: 1 month after surgery
|
1 month after surgery
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FASTTRACK CABG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The research data will be entered on separate forms and stored under a code number, according to prevailing legal requirements. No names or other personal data will be stored. Only the study doctor will hold the information to link the code to the patients. The encoded data will be processed, analysed and reported by the research employees of this study, who have an obligation of secrecy.
Representatives of the sponsor or members of the Ethics Committee (EC) and regulatory authorities within Europe can have access to the medical files in order to inspect the correctness of the research data. Data may be provided to representatives and affiliates of the industries supporting the study: General Electric and HeartFlow Inc. It is possible that the results of this study are presented or published in medical journals; this will always be without mention of the identity of the patients.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Ischemia
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
University of Roma La SapienzaCompletedRosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs) (ROMA)Periprocedural Myocardial NecrosisItaly
-
Lokien van NunenMaquet Cardiovascular; Stichting Toegepaste Wetenschappen (project number 11052)CompletedAcute Myocardial Infarction | Persisting Ischemia | No ReflowNetherlands
-
Tomsk National Research Medical Center of the Russian...CompletedMyocardial Infarction | Myocardial Injury | STEMI | Myocardial NecrosisRussian Federation
-
University Hospital "Sestre Milosrdnice"CompletedSTEMI - ST Elevation Myocardial Infarction | Myocardial ReperfusionCroatia
-
University Hospital, ToulouseThoratec CorporationWithdrawnChronic Myocardial IschemiaFrance
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Deutsches Herzzentrum MuenchenCompletedInfarction, MyocardialGermany
-
Tehran University of Medical SciencesRecruitingMyocardial Infarction | Myocardial Ischemia | Myocardial StunningIran, Islamic Republic of
-
University of TurkuTurku University HospitalEnrolling by invitationMyocardial Infarction | Myocardial InjuryFinland
Clinical Trials on Coronary computed tomography angiography
-
Seoul National University Bundang HospitalCompletedDiabetes Mellitus | Coronary AtherosclerosisKorea, Republic of
-
Erasmus Medical CenterRecruitingCoronary Artery DiseaseNetherlands
-
UMC UtrechtUnknownPostoperative Myocardial Injury
-
Rennes University HospitalCompleted
-
St. Joseph's Healthcare HamiltonCompletedHeart Valve Diseases | Cardiomyopathies | Heart Defects, Congenital | Coronary ArteriosclerosisCanada
-
University of EdinburghNHS Lothian; NHS Greater Glasgow and Clyde; University of Glasgow; Chief Scientist...RecruitingCardiovascular Diseases | Kidney Transplant; ComplicationsUnited Kingdom
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Dutch Heart FoundationCompletedFamilial HypercholesterolemiaNetherlands
-
Asan Medical CenterBoston Scientific CorporationActive, not recruitingCoronary Artery DiseaseKorea, Republic of
-
University of EdinburghNHS Lothian; British Heart FoundationRecruitingCardiovascular DiseasesUnited Kingdom
-
University of MichiganCompletedChest PainUnited States